CD300ld on neutrophils is required for tumour-driven immune suppression
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940 · cited 9×
“STAT3 has essential roles in regulating the differentiation and tolerogenic effects of MDSCs 2,25,26 and can be recruited to the promoter regions of S100a8 and S100a9 (refs.”
BackgroundInfluentialHallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648 · cited 1×
“However, a large proportion of patients show only minimal to no responsiveness to the treatments 5 .”
BackgroundThe role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 1×
“CXCR2 inhibitors reduce tumour growth by blocking PMN-MDSC recruitment and show synergistic effects with PD1 antibodies 32,33 .”
BackgroundTREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
Molgora, M., Esaulova, E., Vermi, W., Hou, J., Chen, Y., Luo, J., Brioschi, S., Bugatti, M., Omodei, A. S., Ricci, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.013 · Cited by 656 · cited 1×
“…), which encodes a surface marker for myeloid cells that mediates leukocyte adhesion and migration 15 , and Trem2 , which encodes a pathology-induced immune signalling hub that counteracts anti-tumour immunity 16 , resulted in specific depletion at the tumour site compared with bone marrow (Fig.”
BackgroundER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74056 · Cited by 365 · cited 1×
“34).”
Ahn, G.-O., Tseng, D., Liao, C.-H., Dorie, M. J., Czechowicz, A., & Brown, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911378107 · Cited by 347 · cited 1×
“…of sgRNAs targeting Itgam (also known as Cd11b ), which encodes a surface marker for myeloid cells that mediates leukocyte adhesion and migration 15 , and Trem2 , which encodes a pathology-induced immune signalling hub that counteracts anti-tumour immunity 16 , resulted in specific depletion at…”
BackgroundMastio, J., Condamine, T., Dominguez, G., Kossenkov, A. V., Donthireddy, L., Veglia, F., Lin, C., Wang, F., Fu, S., Zhou, J., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181952 · Cited by 115
Li, C., Li, W., Xiao, J., Jiao, S., Teng, F., Xue, S., Zhang, C., Sheng, C., Leng, Q., Rudd, C. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404578 · Cited by 60
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Recent study has discovered that CD300ld, a surface molecule on MDSCs, plays a significant role in the immune-suppressive function of MDSCs and may potentially serve as a novel therapeutic target [32].”
BackgroundThe role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
“224 Surgical treatment is effective for early-stage cancer without metastasis, but postoperative recurrence is common.”
BackgroundSelf-citation
Metadata
- Authors
- Wang, C., Zheng, X., Zhang, J., Jiang, X., Wang, J., Li, Y., Li, X., Shen, G., Peng, J., Zheng, P., Gu, Y., Chen, J., Lin, M., Deng, C., Gao, H., Lu, Z., Zhao, Y., & Luo, M.
- Venue
- Nature
- Published
- 2023-09-06
- Volume
- 621
- Issue
- 7980
- Pages
- 830-839
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4386471457
- Cited by
- 181
- References
- 10
- FWCI
- 15.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD300ld on neutrophils is required for tumour-driven immune suppression. https://app.cochat.ai/papers/10.1038/s41586-023-06511-9
- The paper
- Wang, C., Zheng, X., Zhang, J., Jiang, X., Wang, J., Li, Y., Li, X., Shen, G., Peng, J., Zheng, P., Gu, Y., Chen, J., Lin, M., Deng, C., Gao, H., Lu, Z., Zhao, Y., & Luo, M. (2023). CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. https://doi.org/10.1038/s41586-023-06511-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.